List of Excipients in Branded Drug DISKETS

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Hikma Pharmaceuticals USA Inc	DISKETS	methadone hydrochloride	0054-4538	FD&C YELLOW NO. 6
Hikma Pharmaceuticals USA Inc	DISKETS	methadone hydrochloride	0054-4538	MAGNESIUM STEARATE
Hikma Pharmaceuticals USA Inc	DISKETS	methadone hydrochloride	0054-4538	MICROCRYSTALLINE CELLULOSE 101
Hikma Pharmaceuticals USA Inc	DISKETS	methadone hydrochloride	0054-4538	MONOBASIC POTASSIUM PHOSPHATE

DISKETS Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

DISKETS is a methadone hydrochloride 40 mg tablet for oral suspension. Its commercial differentiation depends less on the active ingredient than on dispersion performance, dose uniformity, tamper resistance, palatability, storage stability, and compliance with opioid-treatment-program handling requirements. The strongest opportunities are authorized generic supply, improved high-dose oral-dispersion products, excipient-controlled formulations, and manufacturing partnerships rather than conventional brand expansion.

What is DISKETS and how does its dosage form work?

DISKETS contains methadone hydrochloride and is designed to disperse in water before oral administration. The product is used in opioid-treatment settings and is subject to Schedule II controlled-substance requirements in the United States. Methadone carries substantial risks involving respiratory depression, QT-interval prolongation, drug interactions, and accumulation during dose titration. Product design must therefore preserve dose accuracy and avoid excipient-driven changes in dissolution or absorption. [1]

The dosage form has several technical requirements:

Requirement	Commercial relevance
Rapid and complete dispersion	Supports administration in supervised-treatment settings
Uniform distribution of methadone	Reduces dose variability after tablet dispersion
Mechanical strength	Limits chipping, breakage, and powder loss during handling
Controlled friability	Supports packaging, transport, and counting
Adequate wetting	Prevents floating, clumping, or incomplete dispersion
Acceptable taste and mouthfeel	Improves administration, particularly after dispersion
Low moisture sensitivity	Protects tablet hardness and dissolution performance
Controlled-release avoidance	Maintains the intended immediate-release profile

DISKETS should not be treated as an ordinary immediate-release tablet. The product’s oral-suspension presentation creates a quality profile that includes both solid-dose performance and liquid-dispersion behavior.

What excipients are used in DISKETS?

Public labeling identifies conventional tablet excipients, including lactose monohydrate, microcrystalline cellulose, povidone, crospovidone, sodium starch glycolate, colloidal silicon dioxide, magnesium stearate, flavoring, and colorants. Exact composition should be confirmed against the current FDA-approved prescribing information and the applicable product labeling before formulation or regulatory decisions. [1]

Functional role of the principal excipients

Excipient class	Likely function in DISKETS-type formulation	Key development issue
Lactose monohydrate	Diluent and compressibility aid	Lactose intolerance, moisture behavior, Maillard compatibility
Microcrystalline cellulose	Filler, binder, and tablet-strength contributor	Can affect disintegration and powder compactability
Povidone	Binder and granulation aid	Molecular-weight grade affects viscosity and processing
Crospovidone	Superdisintegrant	Supports rapid breakup without extensive swelling
Sodium starch glycolate	Superdisintegrant	Excessive concentration can produce gelling or uneven dispersion
Colloidal silicon dioxide	Glidant and moisture-management aid	Can alter flow, blend uniformity, and compaction
Magnesium stearate	Lubricant	Over-lubrication can slow wetting and dissolution
Flavoring	Taste masking	Must remain stable and compatible with the dispersion medium
Colorants	Product identification	Can create regulatory, allergen, or market-specific restrictions

The commercial value of these excipients is not based on novelty alone. A replacement formulation must match critical quality attributes, including assay, content uniformity, dissolution, dispersion time, particle-size distribution after dispersion, and stability.

What excipient strategy is strongest for a DISKETS competitor?

The most defensible strategy is a platform built around rapid dispersion and high dose uniformity rather than a simple excipient substitution.

1. Optimize the disintegrant system

Crospovidone and sodium starch glycolate provide different mechanisms. Crospovidone promotes capillary action and rapid tablet breakup. Sodium starch glycolate absorbs water and swells. A balanced combination can reduce dispersion time while limiting clumping.

The formulation should be screened across:

• Disintegrant ratio
• Total disintegrant concentration
• Particle-size grade
• Compression force
• Tablet porosity
• Lubrication time
• Water temperature and volume
• Agitation method

The target is a reproducible dispersion rather than merely a short disintegration time under compendial tablet testing.

2. Control lubricant impact

Magnesium stearate is necessary for manufacturing efficiency but can create hydrophobic surfaces when used at excessive levels or mixed for too long. A controlled lubrication process can improve wetting and preserve dissolution.

Potential development alternatives include sodium stearyl fumarate or lower-impact lubrication systems. These alternatives would require comparative studies because changes in lubricant chemistry can affect tablet strength, ejection force, assay uniformity, dissolution, and stability.

3. Evaluate lactose-free options

A lactose-free version could expand procurement opportunities for institutions that avoid lactose-containing products or seek simplified excipient profiles. Candidate diluents include mannitol, dibasic calcium phosphate, and selected grades of microcrystalline cellulose.

Mannitol may improve mouthfeel and impart a cooling sensation, but it can change tablet compactability and hygroscopic behavior. Dibasic calcium phosphate can provide robust compaction but may alter dissolution and compatibility. A lactose-free formulation would create a potentially protectable formulation distinction if it delivers materially different performance.

4. Improve palatability without creating diversion concerns

Flavor systems must be selected for supervised administration, not consumer-style branding. Excessive sweetness or strong flavor may be counterproductive in opioid-treatment settings. The formulation should prioritize neutral or mildly flavored dispersions with low residual taste.

Taste-masking technologies, including ion-exchange resins or polymer barriers, may increase manufacturing complexity and could affect methadone release. They may also create a more valuable formulation patent if the system reduces taste while maintaining immediate release.

5. Use excipients that support tamper resistance

Tamper resistance is relevant because methadone is a controlled substance. A tablet that disperses in water but resists crushing, powder extraction, or solvent manipulation could offer institutional and public-health value.

Potential technologies include:

• High-hardness matrix systems
• Abuse-deterrent gelling polymers
• Physical barriers to powder formation
• Formulations that become difficult to extract in common solvents
• Packaging with unit-dose or supervised-dispensing features

These approaches must be balanced against the product’s intended dispersion in water. A formulation that impedes legitimate dispersion may fail its principal use case.

What formulation patents could protect a DISKETS competitor?

A conventional excipient list is usually a weak patent position. Stronger claims would connect composition to measurable performance.

Potential patent claim categories

Claim category	Example protected subject matter	Relative strength
Composition	Methadone with a defined disintegrant, binder, diluent, and lubricant ratio	Moderate
Performance	Dispersion within a specified time with defined particle-size distribution	Moderate to strong
Stability	Moisture-controlled formulation maintaining dissolution and hardness over time	Moderate
Taste masking	Specific polymer or resin system that reduces bitterness without delaying release	Moderate to strong
Abuse deterrence	Formulation resisting crushing or extraction while dispersing in water	Strong if technically demonstrated
Manufacturing process	Granulation, lubrication, compression, or coating process producing defined attributes	Moderate
Packaging	Unit-dose moisture barrier or supervised-dispensing system	Usually weaker alone
Method of use	Administration protocol using a defined dispersion volume or handling process	Narrow and potentially difficult to enforce

The strongest formulation patent would claim a technically distinctive relationship among composition, dispersion, dose uniformity, and stability. Broad claims covering methadone with standard excipients would face substantial validity risk from prior art involving immediate-release tablets and oral suspensions.

What FDA regulatory pathway applies to a DISKETS generic?

A conventional generic would generally use an Abbreviated New Drug Application under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The applicant would need to demonstrate pharmaceutical equivalence and bioequivalence, comply with controlled-substance requirements, and address product-specific performance for the oral-suspension presentation. [2]

Relevant development work would include:

1. Pharmaceutical equivalence to the reference product.
2. Comparative dissolution across relevant media.
3. Dispersion testing using the labeled administration procedure.
4. Assay and content-uniformity testing.
5. Stability under long-term and accelerated conditions.
6. Evaluation of container-closure integrity.
7. Demonstration that inactive ingredients do not create safety or administration differences.
8. Controlled-substance manufacturing, storage, recordkeeping, and distribution controls.

A formulation that changes the route, release profile, strength, or clinical use may require a 505(b)(2) application rather than an ANDA. [3]

What is the Orange Book status of DISKETS?

The relevant regulatory question is whether the reference product has an active listing in the FDA Orange Book and whether any patents or regulatory exclusivities are listed against the applicable NDA. Methadone products have been marketed by multiple manufacturers and under multiple dosage forms, so Orange Book analysis must be conducted by exact product, strength, dosage form, NDA, and marketing status. [4]

For a prospective entrant, the commercial assessment should distinguish:

• Active reference listing
• Discontinued but legally marketable reference status
• Listed patents
• Pediatric exclusivity
• Orphan-drug exclusivity, if applicable
• 30-month-stay exposure from a Paragraph IV certification
• Any FDA-approved labeling differences

No commercial decision should rely on a brand name alone.

When does DISKETS lose exclusivity?

DISKETS does not have a single exclusivity date that can be inferred from the brand name. Patent expiration, regulatory exclusivity, and commercial discontinuation are separate issues.

A generic applicant would normally assess:

Exclusivity issue	Effect on entry
Unexpired listed patent	May require Paragraph III or Paragraph IV certification
Regulatory exclusivity	Can delay ANDA approval even if no patent blocks approval
Patent litigation	May trigger a statutory 30-month stay
Product discontinuation	Does not necessarily eliminate reference-product status
Controlled-substance quota	Can restrict supply without creating legal exclusivity
Manufacturing capacity	Can delay launch despite regulatory approval

Paragraph IV litigation risk is likely to be lower for an older methadone tablet than for a recently launched branded drug, but the risk cannot be determined from the brand name without a current Orange Book and patent-docket review.

Which companies could compete with DISKETS?

Competition may come from several product categories:

Competitor type	Strategic advantage	Limitation
Methadone tablet manufacturers	Established active ingredient and manufacturing base	May lack a differentiated dispersion profile
Authorized generic supplier	Lower legal and regulatory risk	Limited pricing differentiation
Methadone oral-solution suppliers	Established supervised-use workflows	Liquid handling, dosing, and diversion concerns
Compounding pharmacies	Custom strengths and local supply	Limited scale and inconsistent procurement status
Long-acting opioid-treatment products	Reduced daily dosing burden	Higher development and regulatory cost
Buprenorphine products	Different safety and treatment profile	Not a direct pharmaceutical substitute for all patients

The largest near-term opportunity is likely institutional supply, particularly opioid-treatment programs, correctional health systems, public-health clinics, and hospital systems. These buyers value continuity, dosage accuracy, logistics, and regulatory reliability more than consumer-facing brand attributes.

What commercial opportunities exist for DISKETS excipients?

Authorized generic or alternate-source supply

An authorized generic or therapeutically equivalent product can compete through supply reliability, contract pricing, and institutional procurement. The value proposition is strongest if the supplier can reduce shortages and maintain controlled-substance compliance.

Lactose-free or simplified excipient formulation

A lactose-free product could support formulary differentiation. The opportunity is commercially meaningful only if the product demonstrates equivalent dispersion, stability, and bioequivalence without a substantial cost penalty.

Improved unit-dose packaging

Unit-dose blister packaging or tamper-evident institutional packaging could reduce counting errors and support supervised administration. Packaging claims are more defensible when linked to moisture protection, dose traceability, and controlled-substance reconciliation.

Abuse-deterrent presentation

An abuse-deterrent methadone tablet could attract institutional interest, but development costs and regulatory expectations would be high. The product would need evidence that deterrence does not interfere with legitimate water dispersion.

Regional licensing

Licensing opportunities may exist in jurisdictions where methadone treatment is expanding but tablet supply is concentrated among a small number of manufacturers. A local partner could provide controlled-substance distribution infrastructure, while the technology owner supplies formulation, process controls, and regulatory documentation.

Excipient supplier partnerships

Excipient manufacturers can create value through co-development of:

• Direct-compression diluent systems
• Low-moisture excipient blends
• Rapid-disintegration platforms
• Taste-masking systems
• Abuse-deterrent polymers
• Continuous-manufacturing feedstocks

The most attractive partnership model would tie the excipient to validated performance specifications and regulatory support rather than sell an undifferentiated commodity ingredient.

How strong is the patent estate for an improved DISKETS formulation?

A new formulation could have a moderate patent position if it combines:

• A defined methadone loading range
• A specific excipient ratio
• A measurable dispersion profile
• A stability advantage
• A manufacturing step that is difficult to design around
• A use case involving supervised administration or abuse deterrence

Patent strength would be weaker for claims limited to replacing lactose with mannitol or changing one standard superdisintegrant for another. Such changes may be commercially useful but can be vulnerable to obviousness challenges.

The most durable portfolio would contain separate families covering composition, process, performance, packaging, and method of use. Geographic filing should prioritize the United States, European Patent Convention states, Canada, Australia, Japan, and markets with established opioid-treatment programs.

What generic launch scenarios exist?

Scenario 1: Standard ANDA launch

A manufacturer develops a conventional equivalent and launches after approval. This is the lowest-cost route but offers limited differentiation and high price pressure.

Scenario 2: Differentiated formulation launch

A lactose-free, faster-dispersing, or better-stabilized product launches under a separate regulatory pathway. This can support higher pricing but requires stronger clinical, pharmaceutical, or regulatory justification.

Scenario 3: Institutional contract launch

The manufacturer secures opioid-treatment-program and government contracts before broad commercial distribution. This reduces promotional expense and aligns the product with the primary purchasing channel.

Scenario 4: Supply-disruption entry

A manufacturer enters during a shortage or after a reference-product discontinuation. FDA shortage status, manufacturing capacity, and controlled-substance quota availability become central commercial variables. [5]

What are the principal manufacturing and IP barriers?

The principal manufacturing barriers are blend uniformity at high active-ingredient potency, tablet robustness, controlled dispersion, moisture control, and validated handling of a Schedule II substance. Methadone’s narrow therapeutic margin increases the cost of process deviations and batch failures.

The principal IP barriers are less likely to involve a broad active-ingredient patent and more likely to involve:

• Product-specific formulation claims
• Listed patents associated with the reference product
• Abuse-deterrent technology
• Dispersion-performance claims
• Trade secrets covering granulation and compression
• Controlled-substance manufacturing approvals and quotas

Trade secrets may be more valuable than patents for process parameters, supplier specifications, and in-process controls that are difficult to reverse engineer.

Key Takeaways

• DISKETS is a methadone hydrochloride 40 mg tablet for oral suspension with value concentrated in dispersion, dose uniformity, handling, and institutional workflow.
• The strongest excipient strategy combines rapid disintegration, controlled wetting, robust compression, and low moisture sensitivity.
• Lactose-free, taste-controlled, and abuse-deterrent variants offer the clearest formulation differentiation.
• A standard excipient substitution is commercially viable but likely has limited patent strength.
• The best patent portfolio would claim composition, performance, process, packaging, and supervised-use features separately.
• Authorized generic supply and institutional contracting are more credible near-term opportunities than broad consumer marketing.
• Orange Book, Paragraph IV, litigation, and exclusivity conclusions must be tied to the exact DISKETS NDA and current FDA records.
• Controlled-substance licensing, quota allocation, manufacturing security, and distribution compliance are core market-entry requirements.

FAQs

Can mannitol replace lactose in a DISKETS-type tablet?

Yes, but the replacement would require comparative evaluation of compression, dispersion, dissolution, stability, taste, and bioequivalence. Mannitol may improve mouthfeel but can change tablet strength and manufacturing behavior.

Is a faster-dispersing methadone tablet automatically patentable?

No. Faster dispersion alone may be obvious unless linked to a non-obvious composition, defined performance range, stability advantage, or manufacturing method.

Would a new DISKETS excipient profile require clinical trials?

Not necessarily. A conventional generic may rely primarily on pharmaceutical equivalence and bioequivalence. A materially different formulation or administration method may require a 505(b)(2) pathway and additional clinical or bridging data.

Can an abuse-deterrent methadone tablet be sold through opioid-treatment programs?

Potentially, but the formulation must preserve legitimate dispersion and dosing requirements while meeting FDA expectations for abuse-deterrent labeling and performance evidence.

Are excipient suppliers eligible for licensing revenue from a DISKETS formulation?

Yes. Licensing can cover a proprietary excipient blend, formulation process, performance specification, manufacturing know-how, or regulatory package. Revenue potential is strongest when the excipient is tied to protected and validated product performance.

References

1. U.S. Food and Drug Administration. (n.d.). DISKETS methadone hydrochloride tablets for oral suspension, prescribing information.
2. U.S. Food and Drug Administration. (2024). Generic drugs: Questions and answers.
3. U.S. Food and Drug Administration. (2024). Applications covered by section 505(b)(2).
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book.
5. U.S. Food and Drug Administration. (2024). Drug shortages.